system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Antineoplastic Agents, Apoptosis, Benzimidazoles, Cell Cycle, Cell Line, Tumor, Cell Proliferation, Child, Child, Preschool, Drug Synergism, Everolimus, Histone-Lysine N-Methyltransferase, Humans, Infant, Infant, Newborn, Inhibitory Concentration 50, Myeloid-Lymphoid Leukemia Protein, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors, Protein-Tyrosine Kinases, Quinolones, Sirolimus, TOR Serine-Threonine Kinases, Translocation, Genetic.
user
Is tKI258 , a multi-tyrosine kinase inhibitor efficacious against human infant/childhood lymphoblastic leukemia in vitro? Context: The goal of the present study was to evaluate if the multiple tyrosine kinase inhibitor (TKI) TKI258 has any treatment value for infant/childhood acute lymphoblatic leukemia (ALL), especially those ALLs bearing the mixed lineage leukemia (MLL) genes. Cell proliferation was measured with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay; cell apoptosis and cell-cycle distribution with flow cytometry. Gene expression at the protein level was determined by western blotting. These ALL cells were extremely sensitive to TKI258 treatment with a concentration for 50% inhibition of cell proliferation (IC50) values in the nanomolar range in vitro. By combination with mTOR inhibitor RAD001, a synergistic effect on cell death and cell proliferation was observed in these cells.
assistant
TKI258 may become a potent therapeutic agent, either alone or in combination with RAD001, for treatment of ALL, especially the entity with MLL genes. Final Decision: yes